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Background: Hepatocellular malignancy in young adults is a prominent feature of hepatitis B virus (HBV) infec-
tion in southern Africa. Here we report a cross-sectional study of liver pathology correlated with biomarkers in
adults with HBV infection in Zambia.
Methods: We analysed liver biopsies from Zambian patients with persistent HBV infection.
Results: We analysed 104 patients with HBV infection and evidence of liver disease. We obtained liver biopsies
from 53 adults; of these, 12 (23%) were hepatitis B e antigen seropositive. The genotype was evenly distributed
between A and E. One biopsy showed malignancy. Stage was 3 or more in 11 of 52 (21%) biopsies free of malig-
nancy and lobular inﬂammation was found in 50 (94%). Neither alanine aminotransferase (ALT) nor the γ-glutamyl
transferase:platelet ratio (GPR) were correlated with the stage of disease but were correlated with total Ishak score
(ρ=0.47, p=0.0004 and ρ=0.33, p=0.02, respectively). Large cell change was observed in 10 of 11 biopsies with
ﬁbrosis stage 3 or more and 16 of 41 with early disease (p=0.005). Serum α-fetoprotein was elevated, although
still within the normal range, in patients with large cell change (median 3.6 [interquartile range {IQR} 1.6–5.1])
compared with those without (1.7 [IQR 1.0–2.8]; p=0.03). Neither ALT nor GPR predicted large cell change.
Conclusions: Large cell change was common in young HBV-infected adults in Zambia. Only serum α-fetopro-
tein was identiﬁed as a biomarker of this phenotype.
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Introduction
Persistent infection with the hepatitis B virus (HBV) is endemic in
Africa, involving many millions of infected people. Early studies
from South Africa1 showed a high incidence of hepatocellular
carcinoma (HCC) in African men, with a further increased inci-
dence in rural communities. A number of factors may predis-
pose to the high burden of malignancy in Africans with
persistent HBV infection, including environmental factors such
as aﬂatoxin B1, viral factors (genotype A1 is associated with a
higher incidence of malignancy) and presumably, host genetic
inﬂuences.2,3 However, we still do not have a full understanding
of the mechanisms underlying the high incidence of HCC in
African men and, of importance, known interventions that may
reduce the cancer rates are not consistently and properly
deployed.
Effective antiviral therapy for persistent HBV infection is becom-
ing widely available throughout the world. Treatment with potent
antiviral drugs (such as tenofovir and entecavir) allows long-term
suppression of viral replication with clear evidence of reversal of
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liver ﬁbrosis.4 The impact of prolonged antiviral therapy on HCC
remains to be determined, although many believe that any
impact will be modest. Persistent HBV infection follows a pro-
longed course with an initial period of high viral replication and
minimal liver inﬂammation (the so-called immunotolerant phase)
followed by episodes of liver inﬂammation that often lead to viral
suppression and the development of an ‘inactive’, hepatitis B e
antigen (HBeAg)-negative phase of infection. This ‘inactive carrier’
phase may persist for decades, but in many it is followed by viral
reactivation and the development of HBeAg-negative disease.
Given the ﬂuctuating natural history of persistent HBV infection
and the prolonged periods of inactivity, experts agree that antiviral
therapy should only be introduced during periods of active dis-
ease, when the greatest beneﬁts are likely to accrue.5–7 The
European Association for the Study of the Liver (EASL) recom-
mends that patients be considered for treatment when they have
HBV DNA levels >2000 IU/mL, have serum alanine aminotransfer-
ase (ALT) levels above the upper limit of normal and evidence of
moderate to severe necroinﬂammation and/or at least moderate
ﬁbrosis on liver biopsy. However, these guidelines were developed
in Asia and developed countries and their value in Africa has been
questioned by recent studies from The Gambia suggesting that
conventional diagnostic approaches may be suboptimal.8,9 There
is also uncertainty about optimal scoring systems for liver biopsies,
and several are available. Here we focus on the Ishak score, a
well-known score focused on inﬂammation.
Zambia has a high prevalence of persistent HBV infection,
with estimates ranging from 4 to 8%; data from the Zambian
National Blood Transfusion Service suggest that prevalence var-
ies across the country. Zambia is bordered by countries known
to have a high incidence of hepatocellular carcinoma,2 but the
true incidence in Zambia is unknown. Clinical experience con-
ﬁrms that, in common with adjacent high-prevalence countries,
cancer occurs in young adults.
In southern Africa, it is common to diagnose hepatocellular
carcinoma in men with chronic HBV in their third decade of life.
Identifying markers of malignant susceptibility in such patients
is of great importance. Large cell change may be such a marker,
but its signiﬁcance is unclear. The increased cell size and nucle-
olar abnormalities suggest that these changes have malignant
potential and could be considered as dysplastic. In this study
we looked at the prevalence of these changes.
We recently initiated a trial of antiviral therapy in Zambia
and here we report that in patients with persistent HBV who
were assessed as potential participants for the study, we found
a high prevalence of histological damage, chieﬂy large cell
change, associated with biochemical parameters that would
not normally lead to consideration of therapy. These data indi-
cate that persistent HBV in Africa may lead to potentially pre-
malignant change in the absence of classical features indicating
a need for antiviral therapy. These ﬁndings suggest that a
reassessment of treatment criteria in Africa will be required to
reduce the burden of this disease.
Study setting and methods
This study was carried out in the University Teaching Hospital
(UTH), Lusaka, Zambia, a secondary and tertiary referral hospital in
the capital city. Recruitment was conducted from January 2014 to
September 2015. Patients were identiﬁed from two sources: blood
donors whose donations were identiﬁed as seropositive for hepa-
titis B surface antigen and patients attending the clinics or on the
wards of UTH who were identiﬁed with any evidence of liver dys-
function or inﬂammation. The data reported here are drawn from
the baseline data collected from patients recruited to the StepHep
study (www.isrctn.com, ISRCTN40785133), which was designed to
test the hypothesis that monotherapy with tenofovir could safely
be followed by monotherapy with lamivudine if full viral suppres-
sion had been achieved during tenofovir treatment; the results of
this longitudinal study will be published elsewhere. Approval for
this study was granted by the University of Zambia Biomedical
Research Ethics Committee on 24 May 2013 (005-02-13) and by
the Zambia Medicines Regulatory Authority on 14 August 2013
(CT040/13) and a favourable ethical opinion was also granted by
the National Health Service National Research Ethics Service
Committee (London City and East) on 10 October 2013. Written
evidence of consent was obtained from all participants.
Patient recruitment
Patients were offered inclusion in the study if they were hepatitis B
surface antigen (HBsAg) seropositive at a single time point. If they
agreed to inclusion, they were further assessed clinically, with
blood drawn for ALT and viral load, and were assessed for liver
biopsy. The inclusion criteria included ALT >35 IU/L, HBV DNA
>2000 IU/mL and evidence of necroinﬂammation on liver biopsy.
When a transient elastography instrument was made available in
June 2015, this was also performed and 5 kPa was added as an
inclusion criterion. Exclusion criteria included HIV infection, a his-
tory of alcohol abuse, a history of anti-tuberculous drug ingestion
or virological evidence of active HCV or HEV infection or serological
evidence of previous infection with schistosomiasis.
Study procedures
Once identiﬁed as having HBV infection and any evidence of liver
inﬂammation, patients were approached and interviewed by a
study physician (BN) or nurse (AK) and informed consent was
sought. The patients were then interviewed, blood was collected
and they were then prepared for liver biopsy, with measurement of
the international normalized ratio and platelet count included in all
cases.When available, transient elastography was performed using
a Fibroscan instrument (Echosens, Paris, France). Two values of cut-
off were used: 7.2 kPa, as recommended by the manufacturer for
chronic HBV infection, and a more exploratory cut-off of 5 kPa,
which would be expected to exclude ﬁbrosis with greater stringency.
Virological assessment
Plasma was obtained from venous blood samples by centrifuga-
tion and aliquots were stored at −80°C so that no more than one
freeze–thaw cycle was required during analysis. HBeAg and anti-
bodies to HDV were detected by enzyme-linked immunosorbent
assay (ELISA; Diasorin, Dartford, UK). For viral load quantiﬁcation,
DNAwas extracted from plasma using Blood DNA minikits (Qiagen,
Hilden, Germany) and ampliﬁed by real-time polymerase chain
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reaction using standard primers (forward: GTGTCTGCGGCG
TTTTATCA; reverse GACAAACGGGCAACATACCTT) in a PRISM 7500
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA), with HBV standards, murine cytomegalovirus and known
HBV-positive controls in every run. For genotyping, HBV DNA was
extracted from 33 plasma samples using a QIAamp MinElute Virus
Spin Kit (Qiagen). A 940-bp amplicon, using previously described
primers10 (HBV_1F 5′TAGGACCCCTGCTCGTGTTACAGG and HBV_4R
5′GAAAGGCCTTGTAAGTTGGCG), was ampliﬁed using Phusion
High-Fidelity DNA polymerase. Sanger sequencing using the above
primers was performed by Source Bioscience (Cambridge, UK).
Sequences were aligned using BioEdit against HBV genotype A and
E reference sequences (GenBank accession codes X02763.1 and
X75657.1, respectively) and submitted to the HBVdb website
(http://hbvdb.ibcp.fr) to conﬁrm genotyping. Surface antigen was
quantiﬁed using the Abbott Architect system (Abbott Diagnostics,
Lake Forest. IL. USA). Schistosomiasis antibodies were tested by
ELISA (Scimedx,Dover, NJ, USA).
Liver biopsies
Biopsies were obtained under local anaesthesia using a 16G
Menghini biopsy needle and immediately placed in formalin-saline
prior to parafﬁn embedding and preparation of haematoxylin and
eosin–stained sections. Biopsies were evaluated by two expert
pathologists (VM and RDG) and both stage and Ishak score were
evaluated. In each case, at least four portal tracts were evaluated
and most cores were at least 4 cm long. In order to help interpret
the signiﬁcance of large cell change when detected, 30 samples of
liver tissue taken post-mortem from adults killed in road trafﬁc
accidents were reviewed (RDG). Also reviewed were 100 consecu-
tive biopsies from HBV-infected patients at St Mary’s Hospital
(London, UK).
Data analysis
Data are reported as discrete or continuous (non-Gaussian) vari-
ables (median and interquartile range [IQR]) and non-parametric
statistics were used throughout. Hypothesis testing employed
Fisher’s exact test for categorical variables and Kruskal–Wallis
test for continuous variables, and correlation was estimated
using Spearman’s rank correlation coefﬁcient (ρ). All authors had
access to the study data and reviewed and approved the ﬁnal
manuscript.
Results
Of 347 adults who were identiﬁed to be seropositive for HBsAg,
104 HIV-seronegative patients were identiﬁed as having evi-
dence of liver inﬂammation, either by ALT >35 IU/L or by a tran-
sient elastography reading >5 kPa; 243 patients had neither of
these characteristics or were HIV co-infected (for a ﬂow dia-
gram, see the Supplementary material). From the remaining
104 patients, 69 underwent needle liver biopsy, but results are
available for only 68, as one was lost in processing. Reasons for
not performing biopsy are shown in Supplementary Table 1.
Baseline characteristics are shown in relation to HBeAg status
(Table 1) or eligibility for treatment (Supplementary Table 2).
Table 1. Baseline characteristics, by ALT and e antigen status
e Antigen status
Positive (n=25) Negative (n=79) p-Value
Sex (male:female) 20:5 68:11 0.60
Age (y) 23 (19–30) 31 (27–42) 0.0002
BMI (kg/m2) 21.2 (20.1–23.0) 22.9 (20.2–25.7) 0.22
Alcohol use currently, n 3 20 0.43
Schistosomiasis, n 1 3 —
HDV antigen positive, n 0 1 —
ALT 72 (45–95) 36 (25–50) 0.001
Platelet count (×109/L) 189 (148–257) 224 (196–272) 0.07
Viral load (log units/ml) 7.9 (5.3–8.3) 2.9 (2.4–3.8) 0.0001
γ-glutamyl transferase 40 (23–83) 42 (26–71) 0.97
HBsAg concentration 12 745 (8994–18 337) 6018 (2538–12 982) 0.003
Fibroscan (kPa)a 7.1 (6.0–18.9) [n=12] 6.2 (5.7–7.1) [n=52] 0.054
Genotype type A: 7 (44%) type A: 10 (59%) 0.49
type E: 9 (56%) type E: 7 (41%)
Data presented as median (IQR) unless stated otherwise. The p-values shown were estimated by Fisher’s exact test for proportions or Kruskal–
Wallis test for continuous variables.
aThe smaller number of people with Fibroscan results in the high ALT group is a consequence of starting the study without Fibroscan; when it
became available we changed the recruitment criteria to include all ALT values. Normal range of ALT <35 IU/L; normal range of γ-glutamyl
transferase <51 IU/L.
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Two patients were conﬁrmed as having HCC, one with high
α-fetoprotein (455–500 kU/L) and one on histology in a patient
who was not initially suspected of having cancer. Two patients
were conﬁrmed as having cirrhosis on histology. Transient elas-
tography data were available for 64 patients (Supplementary
Table 3).
Liver biopsy ﬁndings and biomarkers of disease
severity
Of note, 11 of 52 patients had evidence of ﬁbrosis on histology
(stage 3 or greater). Stage was not related to age (ρ=0.003,
p=0.99), HBe antigenaemia (Table 2) or body mass index (ρ=
−0.01, p=0.95). Lobular inﬂammation was prominent, particu-
larly in those who were e antigen positive (Table 2). Interface
and portal inﬂammation were generally mild and conﬂuent
necrosis was uncommon (Table 2). Of the 11 patients with ﬁbro-
sis on biopsy, 10 had serum ALT >35 IU/L (p=0.03) and 10 had a
viral load of ≥2000 IU/L (p=0.007). ALT was correlated with the
total Ishak score (ρ=0.47, p=0.004; Figure 1) and more particu-
larly with interface inﬂammation (ρ=0.64, p<0.0001) and lobu-
lar inﬂammation (ρ=0.42, p=0.002). However, the predictive
value was weak (Figure 1), such that ALT was elevated in six
patients with Ishak scores ≤2 and was not elevated in ﬁve
patients with Ishak scores ≥4. The initial viral load was corre-
lated with Ishak score (ρ=0.36, p=0.009). To assess histological
evidence of need for treatment, we used standard criteria: Ishak
score ≥4 or stage 3 or greater. Using standard criteria for eligibil-
ity for treatment6 (ALT >35 IU/L and viral load >2000 IU/L), 38
patients would be correctly classiﬁed; however, 9 patients with
histological evidence of a need for treatment would have been
missed and 6 patients unnecessarily treated. The γ-glutamyl
transferase:platelet ratio (GPR) was elevated in 9 of 11 biopsies
with signiﬁcant ﬁbrosis (stage 3 or greater) and 21 of 35 without
(p=0.28), but it was signiﬁcantly associated with eligibility for
treatment (Supplementary Table 2). Transient elastography
readings were not correlated with either histological stage
(p=0.78 by non-parametric test for trend) or Ishak score (ρ=
−0.03, p=0.87).
Large cell change
Large cell change (Figure 2) was noted in 26 of 53 fully evalu-
ated biopsies. Large cell change was clearly more common in
biopsies showing higher stage and was also associated with
Ishak score (Table 3). It was unrelated to age, sex, ALT, viral
load, HBsAg concentration or HBe antigenaemia (Table 3). Large
cell change was, however, associated with increased concentra-
tions of α-fetoprotein, even though these were still within the
normal range (Figure 3). No large cell change was identiﬁed in
30 necropsy samples from road trafﬁc accidents in Zambia, and
in a review of 100 biopsies from HBV-infected patients in
London with various stages of disease, large cell change was
observed in 5, 4 of which had cirrhosis.
Table 2. Histology by eAg status
eAg seronegative eAg seropositive p-Value
Stage 0 8 2 0.32
1 12 2
2 13 3
3 4 2
4 2 2
6 0 1
Interface inﬂammation 0 17 4 0.03
1 13 2
2 7 1
3 2 5
Conﬂuent necrosis 0 38 12 1.00
1 1 0
Lobular inﬂammation 0 2 0 0.004
1 17 0
2 13 5
3 6 7
4 1 0
Portal inﬂammation 0 9 2 0.41
1 21 7
2 9 2
3 0 1
Ishak score total, median (IQR) [range] 5.5 (3.5–7.5) [2–9] 3.0 (2.0–5.0) [0–8] 0.02
The p-values shown were estimated by Fisher’s exact test for proportions or Kruskal–Wallis test for continuous variables.
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Discussion
Although there is wide variation in the precise estimates, there
is no doubt that the global burden of disease due to HBV infec-
tion is huge, with estimates ranging from 240 million to 400
million infected people worldwide11 and with a considerable
burden of cirrhosis and liver cancer.2,8 The prevalence of persist-
ent HBV infection across Africa varies considerably, with esti-
mates from Ghana of 12%12 and Zambian blood bank data
suggesting a prevalence of 5.7%.13 However, there are few data
on which to base prevention policies or treatment decisions in
Africa. Here we show, in a cross-sectional analysis of a patient
population selected to have some evidence of liver inﬂamma-
tion or damage, that there was already advanced disease in a
signiﬁcant proportion of patients, with two having evidence of
cirrhosis and two cancers. Neither ALT nor GPR were fully able to
identify patients with ﬁbrosis and both tests would have missed
patients who were in need of treatment. Large cell change was
present in half of the patients biopsied and was associated with
high-normal α-fetoprotein concentrations in blood.
The principal limitation of this study is its small size, as it was
focused on liver biopsy, and it was therefore not powered to assess
diagnostic accuracy. The data presented here are purely observa-
tional in nature. Self-report of alcohol intake is inaccurate, so we
may have underestimated alcohol intake. However, none of the
biopsies showed histological evidence of alcohol-mediated dam-
age. The third limitation is the uncertainty about the most appro-
priate cut-off for ALT. We used a local rather than an international
reference range. Nevertheless, it is apparent from Figure 1 that no
value of ALT is perfectly discriminating and will always remain
slightly arbitrary.
While the proﬁle of disease in HIV-co-infected patients in Africa
has been the subject of considerable interest,14–16 including chil-
dren,17 paradoxically, fewer studies have been published about
Africans with monoinfection. There are data to suggest that HBV
acquisition in Zambia occurs horizontally in early childhood, rather
than vertically,18 in common with other data from southern
Africa.19 Vaccination programmes will reduce the overall burden
of disease but will not immediately prevent vertically acquired
transmission. HBV vaccination in Zambia is given as part of a
pentavalent vaccine at 6, 10 and 14 weeks of age, although the
World Health Organization recommends that the ﬁrst dose be
administered within 24 h after birth. The delayed ﬁrst dose is a win-
dow of opportunity for transmission during the peri-partum period
and in the early weeks of life.20 It seems likely that the early acqui-
sition of infection during childhood potentiates the development of
hepatocellular cancers in young men,21 but the reason for these
particularly aggressive cancers has not yet been identiﬁed. It is pos-
sible that genetic factors play a part, but case ascertainment is
poor, so an accurate family history is difﬁcult to obtain.
The prevalence of HDV infection in this population appears to be
<1%, consistent with previous estimates in this part of Africa.22,23
The prevalence was considerably higher (5%) in Nigeria.24
Quantitative HBsAg measurement reﬂects the transcription
of closed circular DNA in the hepatocyte.25 We found no evi-
dence that HBsAg concentrations were useful biomarkers of
stage, inﬂammation or the need for treatment. Whether they
Table 3. Large cell change in liver biopsies
Large cell change present (n=26) Large cell change absent (n=27) p-Value
Sex (male:female) 20:6 25:2 0.14
Age (y) 30 (23–40) 28 (23–41) 0.77
ALT (IU/L) 53 (29–86) 38 (27–52) 0.16
e Antigen, n (%) 9 (35) 3/26 (12) 0.10
HBV viral load (log IU/L) 3.8 (2.9–6.1) 3.2 (2.4–4.1) 0.11
α-fetoprotein (kU/ml) 3.6 (1.6–5.1) 1.7 (1.0–2.8) 0.03
Fibroscan (kPa) 6.3 (5.3–7.4) 6.5 (6.0–7.6) 0.66
Stage, n
0 2 9 0.02
1 7 7
2 7 9
3 5 1
4 4 0
5 0 0
6 0 0
Ishak score total 4 (3–6) 3 (2–4) 0.01
Eligible for treatment, n (%) 13 (50) 9 (33) 0.27
HBsAg concentration (IU/ml) 7833 (2784–13 994) [n=23] 5345 (59–13 804) [n=15] 0.28
Data are presented as median (IQR) unless otherwise noted. The p-values shown were estimated by Fisher’s exact test for proportions or
Kruskal–Wallis test for continuous variables. The denominator is as shown at the head of the column except where it was less in the case of e
antigen status—one patient’s serum gave an indeterminate result.
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predict later oncogenesis remains to be elucidated. This under-
lines the general point that biomarkers of disease activity and
progression are urgently needed in Africa. Lemoine et al.26
found that the GPR was a useful biomarker of ﬁbrosis, but we
were unable to conﬁrm this. Zambia and The Gambia are likely
to have different patient populations for several reasons, includ-
ing different ethnicity, the high prevalence of hepatosplenic
schistosomiasis in Zambia and the widespread use of alcohol in
Zambia, which would probably predict that biomarkers of liver
disease would differ in the two countries.
The signiﬁcance of large cell change is as yet unknown, but it
was detected in half of our patients who had liver biopsies, in con-
trast to none of 30 road trafﬁc accident victims (HBV status
unknown) or 5% of patients with advanced HBV infection in
London. Given that in southern Africa it is commonplace to diag-
nose hepatocellular cancer in men in their third decade,2 we must
search for markers of malignant susceptibility in patients with per-
sistent HBV infection, and this high prevalence is of concern. The
change we have identiﬁed is characterized by increased cell size
and nucleolar abnormalities, which necessarily raise the question
as to the malignant potential of these changes and whether they
Figure 2. Histological appearances of large cell change in a liver biopsy
from a Zambian man. In the upper part of the ﬁeld there is a cluster of
hepatocytes showing large cell change characterized by large nuclei in
cells with increased cytoplasm. Haematoxylin and eosin–stained section
(original magniﬁcation ×400).
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Figure 1. Relationships between serum ALT and Ishak scores on histology. Three components of the Ishak score are shown, together with the total
score: (A) interface inﬂammation (Spearman’s ρ=0.64, p<0.001); (B) lobular inﬂammation (ρ=0.41, p=0.002); (C) portal inﬂammation (ρ=0.33,
p=0.01); (D) total Ishak score (ρ=0.47, p=0.004).
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can properly be classiﬁed as dysplastic or not. Further work is
urgently needed to characterize the molecular changes that occur
in these cells and then to follow up these patients carefully with
regular monitoring. The signiﬁcance of large cell change will ultim-
ately determine how we stratify patients with HBV infection in
Africa. If it is actually an innocent marker of regeneration, then
our data suggest that ALT, viral load and possibly GPR may use-
fully contribute to identifying most of those patients who need
treatment. If it is truly a biomarker of impending malignant
change, then either novel biomarkers are needed or all patients
should be treated with a view to cancer prevention. It is important
to note that large cell change was observed more frequently in
Zambia than in patients with chronic HBV infection in London.
Many such patients in London have acquired their infection in
Africa, so it remains a possibility that the large cell change
observed in Zambia may be a consequence of synergy between
HBV and some other environmental exposure.
Supplementary data
Supplementary data are available at Transactions Online (http://
trstmh.oxfordjournals.org/).
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